… for Parkinson's disease has secured funding for Phase II testing. The Michael J. Fox Foundation (MJFF) supported early research of this drug, paving the way for its advancement into clinical … candidate through venture capitalist investments. The company will be conducting two Phase II trials, one that …

… MJFF Associate Director of Research Partnerships, Bernadette Siddiqi (top … as Partners.” Over 300 attendees from pharmaceutical companies, patient advocacy organizations and patient … for volunteers in your area. Learning about research and getting involved shouldn’t be a secretive process. We know …

… the start of Parkinson’s Awareness Month, means a lot. To the average person, it is just an ordinary day, but I’ve … a group of ladies with PD who enjoy each other’s company and raising awareness about our disease. When I … are needed to step up and take every single opportunity to get involved and participate – whether it be in research, …

… We’ve talked often about how drug repurposing (also called repositioning) can … testing and approval processes and therefore are attractive to patients and disease foundations. However, the lack of commercial incentive for drug repurposing makes the practice …

… called pS129 alpha-synuclein, can serve as an in indicator of disease progression. Measuring its amount in the … which bathes the brain and spinal cord, can help determine how advanced Parkinson's disease is in each case. We have … disease: If its evaluation is successful, this test will become one of the critical tools for measuring and monitoring …

… pm ET In the January 16, 2014 Webinar Dave Iverson talks to a woman with Parkinson's about her long journey to the … current projects in the pursuit of a definitive diagnostic test for PD, and how this would alter Parkinson's diagnosis and patient care. …